Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for PRGO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 349.40M
March 31, 2026 -12.40M
December 31, 2025 -24.50M
September 30, 2025 -21.40M
June 30, 2025 -3.80M
March 31, 2025 -25.70M
December 31, 2024 -37.10M
September 30, 2024 212.70M
June 30, 2024 -73.30M
March 31, 2024 -23.50M
December 31, 2023 -22.80M
September 30, 2023 -30.70M
June 30, 2023 -4.40M
March 31, 2023 -19.60M
December 31, 2022 -26.00M
September 30, 2022 -20.90M
June 30, 2022 -1.974B
March 31, 2022 62.70M
December 31, 2021 -41.90M
September 30, 2021 1.454B
June 30, 2021 -21.80M
March 31, 2021 -114.00M
December 31, 2020 -127.50M
September 30, 2020 -38.60M
June 30, 2020 53.10M
Date Value
March 31, 2020 -74.80M
December 31, 2019 -106.30M
September 30, 2019 -651.80M
June 30, 2019 -68.10M
March 31, 2019 230.10M
December 31, 2018 -46.10M
September 30, 2018 -51.50M
June 30, 2018 -27.10M
March 31, 2018 -2.10M
December 31, 2017 66.00M
September 30, 2017 -9.90M
June 30, 2017 -5.80M
March 31, 2017 2.288B
December 31, 2016 94.50M
September 30, 2016 38.40M
June 30, 2016 60.80M
March 31, 2016 -368.70M
December 31, 2015 1.814B
September 30, 2015 -367.30M
June 30, 2015 -2.075B
March 31, 2015 -246.20M
June 30, 2014 -59.10M
March 31, 2014 -46.20M
December 31, 2013 -1.564B
September 30, 2013 -35.80M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Avadel Pharmaceuticals Plc -8.788M
Jazz Pharmaceuticals Plc 354.90M
GH Research Plc 6.295M
Cosmo NV --
Viatris, Inc. -51.60M